EA200901145A1 - Применение рибофлавина в лечении гипертензии - Google Patents

Применение рибофлавина в лечении гипертензии

Info

Publication number
EA200901145A1
EA200901145A1 EA200901145A EA200901145A EA200901145A1 EA 200901145 A1 EA200901145 A1 EA 200901145A1 EA 200901145 A EA200901145 A EA 200901145A EA 200901145 A EA200901145 A EA 200901145A EA 200901145 A1 EA200901145 A1 EA 200901145A1
Authority
EA
Eurasian Patent Office
Prior art keywords
riboflavin
treatment
provides
patient
hypertension
Prior art date
Application number
EA200901145A
Other languages
English (en)
Other versions
EA019281B1 (ru
Inventor
Мэри Уорд
Хелен Макналти
Джералдин Хориган
Шон Стрейн
Джон Скотт
Джон Пёрвис
Original Assignee
Юниверсити Оф Ольстер
Уэстерн Хелс Энд Сошиал Кеа Траст
Дзе Провост, Феллоус Энд Сколарс Оф Дзе Коллидж Оф Дзе Хоули Энд Андивайдед Тринити Оф Квин Элизабет Ниэр Дублин
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Ольстер, Уэстерн Хелс Энд Сошиал Кеа Траст, Дзе Провост, Феллоус Энд Сколарс Оф Дзе Коллидж Оф Дзе Хоули Энд Андивайдед Тринити Оф Квин Элизабет Ниэр Дублин filed Critical Юниверсити Оф Ольстер
Publication of EA200901145A1 publication Critical patent/EA200901145A1/ru
Publication of EA019281B1 publication Critical patent/EA019281B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение предлагает применение рибофлавина в производстве лекарственного средства для лечения или профилактики повышенного артериального давления у пациента, гомозиготного или гетерозиготного на MTHFR C677T полиморфизм. Изобретение также предлагает фармацевтический продукт для лечения или профилактики повышенного артериального давления у пациента, гомозиготного или гетерозиготного на MTHFR C677T полиморфизм, включающий фармацевтически эффективное количество антигипертензивного агента и рибофлавина, и изобретение дополнительно предлагает способ лечения такого пациента, включающий введение рибофлавина.
EA200901145A 2007-02-23 2008-02-22 Применение рибофлавина в лечении гипертензии EA019281B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0703514.0A GB0703514D0 (en) 2007-02-23 2007-02-23 Use of riboflavin
PCT/EP2008/001437 WO2008101724A1 (en) 2007-02-23 2008-02-22 Use of riboflavin in the treatment of hypertension

Publications (2)

Publication Number Publication Date
EA200901145A1 true EA200901145A1 (ru) 2010-02-26
EA019281B1 EA019281B1 (ru) 2014-02-28

Family

ID=37945596

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901145A EA019281B1 (ru) 2007-02-23 2008-02-22 Применение рибофлавина в лечении гипертензии

Country Status (10)

Country Link
US (1) US20100324019A1 (ru)
EP (1) EP2139488B1 (ru)
JP (1) JP5577100B2 (ru)
CN (1) CN101678030B (ru)
CA (1) CA2679217C (ru)
EA (1) EA019281B1 (ru)
ES (1) ES2393144T3 (ru)
GB (1) GB0703514D0 (ru)
MX (1) MX2009009020A (ru)
WO (1) WO2008101724A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2656897T3 (es) * 2012-08-16 2018-02-28 Critical Care Diagnostics, Inc. Procedimientos de predicción del riesgo de desarrollar hipertensión
CN103721259A (zh) * 2014-01-07 2014-04-16 深圳奥萨医药有限公司 血管紧张素ⅱ受体阻断剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物
CN109295216A (zh) * 2018-11-06 2019-02-01 宁波艾捷康宁生物科技有限公司 预测高血压个体化药物药效的snp位点和检测试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
DE3682208D1 (de) * 1986-12-18 1991-11-28 Kurt Heinz Bauer Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.
US6485959B1 (en) * 1998-10-07 2002-11-26 Cedars Sinai Medical Center Cell preconditioning and cryopresevation medium
CN1136895C (zh) * 2001-05-24 2004-02-04 魏振鸣 一种治疗冠心病的药物
WO2006085128A1 (en) * 2005-02-09 2006-08-17 Wockhardt Limited Cardiovascular therapeutic combinations
US7838526B2 (en) * 2005-08-05 2010-11-23 Esther Baldinger Method of treating neurological disorders

Also Published As

Publication number Publication date
CA2679217C (en) 2016-05-17
EA019281B1 (ru) 2014-02-28
MX2009009020A (es) 2010-02-17
EP2139488B1 (en) 2012-08-15
GB0703514D0 (en) 2007-04-04
EP2139488A1 (en) 2010-01-06
CN101678030A (zh) 2010-03-24
WO2008101724A1 (en) 2008-08-28
JP5577100B2 (ja) 2014-08-20
US20100324019A1 (en) 2010-12-23
JP2010519235A (ja) 2010-06-03
CA2679217A1 (en) 2008-08-28
WO2008101724A8 (en) 2009-10-08
CN101678030B (zh) 2013-06-05
ES2393144T3 (es) 2012-12-18

Similar Documents

Publication Publication Date Title
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2008021113A3 (en) Transdermal methods and systems for treating alzheimer's disease
WO2009137465A3 (en) Compositions for treatment or prevention of pathological cardiac remodeling and heart failure
MX2007006063A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central.
WO2006110175A3 (en) Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
UA97795C2 (ru) Дейтерированные производные катехоламина и медикаменты, которые содержат упомянутые соединения
TW200637546A (en) Combination therapy
AR052565A1 (es) Prevencion y tratamiento de trastornos tromboembolicos
BRPI0517976A (pt) métodos de tratamento
WO2010045417A3 (en) Combination therapies for the treatment of obesity
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
WO2007023072A3 (en) Use of ambroxol for the treatment of rhinovirus infections
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
WO2006113718A3 (en) Compositions for the treatment of neoplasms
MY154941A (en) Treatment and prevention of multi-drug resistance
GB2446341A (en) Method and system for transdermal drug delivery
WO2010045522A3 (en) Combination therapies for the treatment of obesity
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии
ATE489380T1 (de) Hydratformen von amg706
WO2006053014A3 (en) Selective inhibition of rock1 in cardiac therapy
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
WO2009047505A3 (en) Dexanabinol with inhibitors of braf or mek for the treatment of melanoma
WO2008064138A3 (en) Personalized therapeutic treatment process
SE0102887D0 (sv) New formulation

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU